Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Gut Pathogens
Published in: Gut Pathogens 1/2023

Open Access 01-12-2023 | Helicobacter Pylori | Review

Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report

Authors: Ari Fahrial Syam, Muhammad Miftahussurur, Dadang Makmun, Murdani Abdullah, Abdul Aziz Rani, Gontar Alamsyah Siregar, Marcellus Simadibrata, Nasrul Zubir, I. Dewa Nyoman Wibawa, Hery Djagat Purnomo, Chudahman Manan, Dharmika Djojoningrat, Achmad Fauzi, Kaka Renaldi, Hasan Maulahela, Amanda Pitarini Utari, Rabbinu Rangga Pribadi, Virly Nanda Muzellina, Saskia Aziza Nursyirwan, Muhammad Firhat Idrus, Ruswhandi Ruswhandi, Titong Sugihartono, Muhammad Begawan Bestari, Putut Bayupurnama, Triyanta Yuli Pramana, Bogi Pratomo Wibowo, Achmad Fuad Bakry, Fardah Akil, Andi Muhammad Luthfi Parewangi, Haris Widita, I Ketut Mariadi, Ignatia Sinta Murti, Ali Imron Yusuf, Arles Arles, Fauzi Yusuf, Bradley Jimmy Waleleng, Abimanyu Abimanyu, Yustar Mulyadi, Maria Inge Lucida, Yudith Annisa Ayu Rezkhita, Ricky Indra Alfaray, Yoshio Yamaoka

Published in: Gut Pathogens | Issue 1/2023

Login to get access

Abstract

Dyspepsia still becomes a major challenge in upper gastrointestinal disease in Indonesia. This disease often correlated with Helicobacter pylori infection. However, the prevalence of this bacterium is generally low in Indonesia. Therefore, several considerations should be taken into consideration during the management of dyspepsia and H. pylori infection. “Management of dyspepsia and H. pylori infection in Indonesia: The Indonesian consensus report” comprises information gathered from 22 gastroenterology centers across Indonesia. The experts gathered to evolve a consensus, that consists of the statements, grades of recommendations, evidence levels, and rationales for the dyspepsia and H. pylori infection management for daily clinical practice. The report explains several aspects from the updated epidemiology information to comprehensive management therapy. After the experts worked together on all statements in the recommendations, the results are presented with the final agreement as a consensus to help clinicians in understanding, diagnosing, and treating dyspepsia and H. pylori infection patients in daily clinical practice in Indonesia.
Literature
1.
Syam AF, Simadibrata M, Makmun D, Abdullah M, Fauzi A, Renaldi K, Maulahela H, Utari AP. National consensus on management of dyspepsia and Helicobacter pylori infection. Acta Med Indones. 2017;49(3):279–87.PubMed
2.
Yang YX, Brill J, Krishnan P, Leontiadis G. American Gastroenterological Association Clinical Practice Guidelines C: American Gastroenterological Association Institute Guideline on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions. Gastroenterology. 2015;149(4):1082–7.PubMedCrossRef
3.
Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. Helicobacter pylori induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech. 2017;10(2):89–104.PubMedPubMedCentralCrossRef
4.
Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988–1013.PubMedCrossRef
5.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Off J Am Coll Gastroenterol|ACG 2017; 112(2).
6.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.PubMedCrossRef
7.
Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol. 2018;33(1):37–56.PubMedCrossRef
8.
Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51-69.e14.PubMedCrossRef
9.
Liou J-M, Malfertheiner P, Lee Y-C, Sheu B-S, Sugano K, Cheng H-C, Yeoh K-G, Hsu P-I, Goh K-L, Mahachai V, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093–112.PubMedCrossRef
10.
Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2): e12475.PubMedCrossRef
11.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.PubMedCrossRef
12.
Miwa H, Ghoshal UC, Fock KM, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Hongo M, Hou X, Kachintorn U, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012;27(4):626–41.PubMedCrossRef
13.
Yamawaki H, Futagami S, Wakabayashi M, Sakasegawa N, Agawa S, Higuchi K, Kodaka Y, Iwakiri K. Management of functional dyspepsia: state of the art and emerging therapies. Therapeut Adv Chronic Dis. 2018;9(1):23–32.CrossRef
14.
Carbone F, Holvoet L, Vanuytsel T, Tack J. Rome III functional dyspepsia symptoms classification: severity vs frequency. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2017;29(6):e13024.CrossRef
15.
Miftahussurur M, Alfaray RI, Rezkitha YAA, Fauzia KA, Maulahela H, Muzellina VN, Rotty LSM. Macronutrient and micronutrient intake in dietary habits contributed to dyspeptic symptoms in Indonesia. Gac Med Caracas. 2021.
16.
Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23(3):325–33.PubMedPubMedCentralCrossRef
17.
Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Fock KM, Hongo M, Hou X, Kachintorn U, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012;18(2):150–68.PubMedPubMedCentralCrossRef
18.
Makmun D. Present status of endoscopy, therapeutic endoscopy and the endoscopy training system in Indonesia. Digest Endosc. 2014;26(Suppl 2):2–9.CrossRef
19.
Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049–57.PubMedCrossRef
20.
NICE: Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. In. UK: NICE (The National Institute for Health and Care Excellence); 2014.
21.
Francis P, Zavala SR. Functional Dyspepsia. In: StatPearls. Treasure Island (FL); 2023.
22.
Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, Talley NJ. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92.PubMedCrossRef
23.
Stanghellini V. Functional dyspepsia and irritable bowel syndrome: beyond rome IV. Digest Dis. 2017;35(Suppl 1):14–7.CrossRef
24.
25.
Internal Clinical Guidelines T: National Institute for Health and Care Excellence: Clinical Guidelines. In: Dyspepsia and Gastro-Oesophageal Reflux Disease: Investigation and Management of Dyspepsia, Symptoms Suggestive of Gastro-Oesophageal Reflux Disease, or Both. London: National Institute for Health and Care Excellence (UK) Copyright© National Institute for Health and Care Excellence, 2014; 2014
26.
27.
Odeghe EA, Adeniyi OF, Oyeleke GK, Keshinro SO. Use of alarm features in predicting significant endoscopic findings in Nigerian patients with dyspepsia. Pan Afr Med J. 2019;34:66.PubMedPubMedCentralCrossRef
28.
Fraser AG, Schreuder V, Chua LE, Moore L. Follow up after successful eradication of Helicobacter pylori: symptoms and reinfection. J Gastroenterol Hepatol. 1998;13(6):555–9.PubMedCrossRef
29.
Lu Y, Chen M, Huang Z, Tang C. Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis. PLoS ONE. 2016;11(6): e0157798.PubMedPubMedCentralCrossRef
30.
31.
Zhang X, Tang C, Tian D, Hou X, Yang Y. Management of digestive disorders and procedures associated with COVID-19. Am J Gastroenterol. 2020;115(8):1153–5.PubMedCrossRef
32.
Elshazli RM, Kline A, Elgaml A, Aboutaleb MH, Salim MM, Omar M, Munshi R, Mankowski N, Hussein MH, Attia AS, et al. Gastroenterology manifestations and COVID-19 outcomes: a meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740–68.PubMedPubMedCentralCrossRef
33.
Chen R, Yu Y-l, Li W, Liu Y, Lu J-x, Chen F, Zhou Q, Xia Z-y, Gao L, Meng Q-t et al. Gastrointestinal symptoms associated with unfavorable prognosis of COVID-19 patients: a retrospective study. Front Med. 2020; 7(815).
34.
Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao S-Y. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007–14.PubMedPubMedCentralCrossRef
35.
Azwar MK, Kirana F, Kurniawan A, Handayani S, Setiati S. Gastrointestinal presentation in COVID-19 in Indonesia: a case report. Acta Med Indones. 2020;52(1):63–7.PubMed
36.
Djunaidi AM, Wirya AY. Urticarial manifestation in COVID-19 infection: a case report. Bali Dermatol Venereol J. 2020; 3(1).
37.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.PubMedPubMedCentralCrossRef
38.
Panayi AC, Flores-Huidobro A, Wu M, Endo Y, Hamaguchi R, Haug V, Ma C, Orgill DP. Adherence to personal protective equipment guidelines during the COVID-19 pandemic: a worldwide survey study. Br J Surg. 2020;107(11):e526–8.PubMedPubMedCentral
39.
Maulahela H, Syam AF, Renaldi K, Bestari MB, Sutikno R, Abdullah M, Simadibrata M, Makmun D. A clinical and procedural guideline for gastrointestinal endoscopy units during COVID-19 pandemic era. Acta Med Indones. 2020;52(4):431–5.PubMed
40.
Pedoman Tatalaksana COVID-19 Indonesia edisi 4 (ENG: The 4th Edition of Indonesian COVID-19 Management Guideline). In: 4 edn. Indonesia: The Indonesia Society of Respirology, The Indonesian Internist Association, The Indonesian Heart Association, The Indonesian Pediatric Society, The Indonesian Society Of Anesthesiology and Intensive Therapy (Satuan Tugas Penanganan COVID-19); 2022.
41.
Lowe DM, Brown LK, Chowdhury K, Davey S, Yee P, Ikeji F, Ndoutoumou A, Shah D, Lennon A, Rai A, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): a randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med. 2022;19(10): e1004120.PubMedPubMedCentralCrossRef
42.
Law MF, Ho R, Law KWT, Cheung CKM. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. World J Hepatol. 2021;13(12):1850–74.PubMedPubMedCentralCrossRef
43.
Informatorium of COVID-19 drugs in Indonesia. In: 1 edn. Indonesia: The Indonesian Food and Drug Authority 2020.
44.
Alfaray RI, Saruuljavkhlan B, Ansari S, Fauzia KA, Yamaoka Y. Review: epidemiology of Helicobacter pylori infection. Microbiota Health Dis. 2022;4(3): e733.
45.
Miftahussurur M, Waskito LA, Fauzia KA, Mahmudah I, Doohan D, Adnyana IK, Khomsan A, Ratnasari N, Rezkitha YAA. Overview of Helicobacter pylori infection in Indonesia: what distinguishes it from countries with high gastric cancer incidence? Gut and liver. 2021;15(5):653–65.PubMedCrossRef
46.
Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi, Akil F, Uswan WB, Simanjuntak D, Uchida T, et al. Risk factors and prevalence of Helicobacter pylori in five largest islands of Indonesia: a preliminary study. PloS One. 2015; 10(11):e0140186.
47.
Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Wibawa IDN, Rezkitha YAA, Siregar G, Yulizal OK, Akil F, Uwan WB, et al. Analysis of risks of gastric cancer by gastric mucosa among Indonesian ethnic groups. PLoS ONE. 2019;14(5): e0216670.PubMedPubMedCentralCrossRef
48.
Syam AF, Waskito LA, Rezkitha YAA, Simamora RM, Yusuf F, Danchi KE, Bakry AF, Miftahussurur M, Yamaoka Y. Helicobacter pylori in the Indonesian Malays descendant might be imported from other ethnics. 2021.
49.
Aziz RK, Khalifa MM, Sharaf RR. Contaminated water as a source of Helicobacter pylori infection: a review. J Adv Res. 2015;6(4):539–47.PubMedCrossRef
50.
Amaral O, Fernandes I, Veiga N, Pereira C, Chaves C, Nelas P, Silva D. Living conditions and Helicobacter pylori in adults. Biomed Res Int. 2017;2017:9082716–9082716.PubMedPubMedCentralCrossRef
51.
Miftahussurur M, Shiota S, Suzuki R, Matsuda M, Uchida T, Kido Y, Kawamoto F, Maimunah U, Adi P, Rezkitha Y, et al. Identification of Helicobacter pylori infection in symptomatic patients in Surabaya, Indonesia, using five diagnostic tests. Epidemiol Infect. 2015;143(5):986–96.PubMedCrossRef
52.
53.
Miftahussurur M, Alfaray RI, Fauzia KA, Dewayani A, Doohan D, Waskito LA, Rezkitha YAA, Utomo DH, Somayana G, FahrialSyam A, et al. Low-grade intestinal metaplasia in Indonesia: insights into the expression of proinflammatory cytokines during Helicobacter pylori infection and unique East-Asian CagA characteristics. Cytokine. 2023;163: 156122.PubMedCrossRef
54.
M.S. A, G.L. K. Sodium consumption in Southeast Asia: an updated review of intake levels and dietary sources in six countries. In: Preventive nutrition: nutrition and health. In: A. B, R. D: Springer, Cham.; 2015.
55.
Tokudome S, SamsuriaSoeripto WD, Triningsih FX, Suzuki S, Hosono A, Triono T, Sarjadi IW, Miranti IP, Ghadimi R, Moore MA, et al. Helicobacter pylori infection appears essential for stomach carcinogenesis: observations in Semarang, Indonesia. Cancer Sci. 2005;96(12):873–5.PubMedCrossRef
56.
Tokudome S, Soeripto, Triningsih FX, Ananta I, Suzuki S, Kuriki K, Akasaka S, Kosaka H, Ishikawa H, Azuma T et al. Rare Helicobacter pylori infection as a factor for the very low stomach cancer incidence in Yogyakarta, Indonesia. Cancer Lett. 2005; 219(1):57–61.
57.
Tan MC, Graham DY. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointest Endosc. 2019;90(3):457–60.PubMedPubMedCentralCrossRef
58.
Graham S, Haughey B, Marshall J, Brasure J, Zielezny M, Freudenheim J, West D, Nolan J, Wilkinson G. Diet in the epidemiology of gastric cancer. Nutr Cancer. 1990;13(1–2):19–34.PubMedCrossRef
59.
Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura—a randomized controlled trial. Am J Gastroenterol. 2005;100(6):1265–70.PubMedCrossRef
60.
Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: a concise review. World J Gastroenterol. 2014;20(34):11950–61.PubMedPubMedCentralCrossRef
61.
62.
Sianturi GN, Soebaryo RW, Zubier F, Syam AF. Helicobacter pylori infection: prevalence in chronic urticaria patients and incidence of autoimmune urticaria (study in Dr. Cipto Mangunkusumo Hospital, Jakarta). Acta Med Indonesiana. 2007;39(4):157–62.
63.
64.
Miftahussurur M, Nusi IA, Akil F, Syam AF, Wibawa IDN, Rezkitha YAA, Maimunah U, Subsomwong P, Parewangi ML, Mariadi IK, et al. Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia. PLoS ONE. 2017;12(5): e0176203.PubMedPubMedCentralCrossRef
65.
Doohan D, Fauzia KA, Rathnayake J, Lamawansa MD, Waskito LA, Tuan VP, Dashdorj A, Kabamba ET, Phuc BH, Ansari S, et al. Pepsinogen and serum IgG detection is a valuable diagnostic method for Helicobacter pylori infection in a low-prevalence country: a report from Sri Lanka. Diagnostics (Basel). 2021;11(8):1364.PubMedCrossRef
66.
Miftahussurur M, Waskito LA, Fauzia KA, Mahmudah I, Doohan D, Adnyana IK, Khomsan A, Ratnasari N, Rezkitha YAA. Overview of Helicobacter pylori infection in Indonesia: what distinguishes it from countries with high gastric cancer incidence? Gut and Liver. 2020.
67.
Bytzer P. Can noninvasive Helicobacter pylori testing save endoscopy? Endoscopy. 1997;29(7):649–51.PubMedCrossRef
68.
Gisbert JP, Calvet X. Helicobacter pylori “Test-and-Treat” strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol. 2013;4(3):e32–e32.PubMedPubMedCentralCrossRef
69.
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2015;21(40):11221–35.PubMedPubMedCentralCrossRef
70.
Atkinson NS, Braden B. Helicobacter pylori infection: diagnostic strategies in primary diagnosis and after therapy. Dig Dis Sci. 2016;61(1):19–24.PubMedCrossRef
71.
Nurdin WKE, Kusmardi K. Comparison of Helicobacter pylori detection using immunohistochemistry and giemsa and its association with morphological changes in active chronic gastritis. Indonesian J Gastroenterol Hepatol Digest Endosc. 2016;17(1):21–7.CrossRef
72.
Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella Mele M, Bilardi C, Borro P, Dulbecco P, Tessieri L, Mansi C, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther. 2000;14(7):893–900.PubMedCrossRef
73.
Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20(29):9912–21.PubMedPubMedCentralCrossRef
74.
Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195–205.PubMed
75.
Bestari MB, Palungkun IG, Hernowo BS, Abdurachman SA, Nugraha ES. Low-stage gastric MALT lymphoma causing life-threatening upper gastrointestinal bleeding. Case Rep Gastroenterol. 2019;13(3):376–84.PubMedPubMedCentralCrossRef
76.
Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc. 1994;40(3):342–5.PubMedCrossRef
77.
Glover B, Teare J, Ashrafian H, Patel N. The endoscopic predictors of Helicobacter pylori status: a meta-analysis of diagnostic performance. Therapeut Adv Gastrointest Endosc. 2020;13:2631774520950840.CrossRef
78.
Kamada T, Haruma K, Inoue K, Shiotani A. Helicobacter pylori infection and endoscopic gastritis—Kyoto classification of gastritis. Nihon Shokakibyo Gakkai zasshi Japan J Gastro-enterol. 2015;112(6):982–93.
79.
Nishibayashi H, Kanayama S, Kiyohara T, Yamamoto K, Miyazaki Y, Yasunaga Y, Shinomura Y, Takeshita T, Takeuchi T, Morimoto K, et al. Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. J Gastroenterol Hepatol. 2003;18(12):1384–91.PubMedCrossRef
80.
Bazin T, NchareMfondi A, Julie C, Émile J-F, Raymond J, Lamarque D. Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors. United Eur Gastroenterol J. 2018;6(8):1267–73.CrossRef
81.
Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, et al. Surveillance of Helicobacter pylori antibiotic susceptibility in Indonesia: different resistance types among regions and with novel genetic mutations. PLoS ONE. 2016;11(12): e0166199.PubMedPubMedCentralCrossRef
82.
Leontiadis GI, Moayyedi P, Ford AC. Helicobacter pylori infection. BMJ Clin Evid. 2009.
83.
Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345–58.PubMedPubMedCentralCrossRef
84.
Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therap Adv Gastroenterol. 2020;13:1756284820968736.PubMedPubMedCentralCrossRef
85.
Miftahussurur M, Fauzia KA, Nusi IA, Setiawan PB, Syam AF, Waskito LA, Doohan D, Ratnasari N, Khomsan A, Adnyana IK, et al. E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study. BMC Res Notes. 2020;13(1):22.PubMedPubMedCentralCrossRef
86.
Hagymasi K, Mullner K, Herszenyi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12(6):873–88.PubMedCrossRef
87.
Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, Maulahela H, Akil F, Uwan WB, Siregar G, et al. CYP2C19 polymorphisms in Indonesia: comparison among ethnicities and the association with clinical outcomes. Biology (Basel). 2021;10(4):300.PubMed
88.
McNulty CA, Lasseter G, Shaw I, Nichols T, D’Arcy S, Lawson AJ, Glocker E. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther. 2012;35(10):1221–30.PubMedCrossRef
89.
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106–14.PubMedCrossRef
90.
Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59(2):153–61.PubMedCrossRef
91.
Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–26.PubMedCrossRef
92.
Syam AF, Rani AA, Abdullah M, Manan C, Makmun D, Simadibrata M, Djojoningrat D, Sato T. Accuracy of Helicobacter pylori stool antigen for the detection of Helicobacter pylori infection in dyspeptic patients. World J Gastroenterol. 2005;11(3):386–8.PubMedPubMedCentralCrossRef
93.
Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Annal Transl Med. 2015;3(1):9–9.
94.
Miftahussurur M, Yamaoka Y. Diagnostic methods of Helicobacter pylori infection for epidemiological studies: critical importance of indirect test validation. Biomed Res Int. 2016;2016:4819423.PubMedPubMedCentralCrossRef
Metadata
Title
Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report
Authors
Ari Fahrial Syam
Muhammad Miftahussurur
Dadang Makmun
Murdani Abdullah
Abdul Aziz Rani
Gontar Alamsyah Siregar
Marcellus Simadibrata
Nasrul Zubir
I. Dewa Nyoman Wibawa
Hery Djagat Purnomo
Chudahman Manan
Dharmika Djojoningrat
Achmad Fauzi
Kaka Renaldi
Hasan Maulahela
Amanda Pitarini Utari
Rabbinu Rangga Pribadi
Virly Nanda Muzellina
Saskia Aziza Nursyirwan
Muhammad Firhat Idrus
Ruswhandi Ruswhandi
Titong Sugihartono
Muhammad Begawan Bestari
Putut Bayupurnama
Triyanta Yuli Pramana
Bogi Pratomo Wibowo
Achmad Fuad Bakry
Fardah Akil
Andi Muhammad Luthfi Parewangi
Haris Widita
I Ketut Mariadi
Ignatia Sinta Murti
Ali Imron Yusuf
Arles Arles
Fauzi Yusuf
Bradley Jimmy Waleleng
Abimanyu Abimanyu
Yustar Mulyadi
Maria Inge Lucida
Yudith Annisa Ayu Rezkhita
Ricky Indra Alfaray
Yoshio Yamaoka
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2023
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-023-00551-2

Other articles of this Issue 1/2023

Gut Pathogens 1/2023 Go to the issue

Research

The beneficial effects of commensal E. coli for colon epithelial cell recovery are related with Formyl peptide receptor 2 (Fpr2) in epithelial cells

Research

Gut microbiota and autism spectrum disorders: where do we stand?

Research

Correlation between gut microbiota composition, enteric infections and linear growth impairment: a case–control study in childhood stunting in Pidie, Aceh, Indonesia

Research

Invasion of intestinal cells by Staphylococcus warneri, a member of the human gut microbiota

Research

Establishment of persistent enteric mycobacterial infection following streptomycin pre-treatment

Research

Polymorphism of virulence genes and biofilm associated with in vitro induced resistance to clarithromycin in Helicobacter pylori
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits